Are the high mortality rates in dialysis patients mainly due to cardiovascular causes?

proliferator-activated receptor-gamma in peritoneal dialysis patients will it reduce inflammation, atherosclerosis, calcification and improve survival of peritoneal dialysis patients. Hong Kong, People’s Republic of China: Hospital Authority. (21 March 2011, date last accessed) 28. Duman S, Sen S, Duman C et al. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs 2005; 28: 156–163 29. Li PK, Cheng YL. Therapeutic options for preservation of residual renal function in patients on peritoneal dialysis. Perit Dial Int 2007; 27 (Suppl 2): S158–S163 30. http://clinicaltrials.gov/ct2/show/NCT01041963 The effect of enalapril and losartan on peritoneal membrane in continuous ambulatory peritoneal dialysis patients. Chulalongkorn University (21 March 2011, date last accessed) 31. Duman S, Sen S, Sozmen EY et al. Atorvastatin improves peritoneal sclerosis induced by hypertonic PD solution in rats. Int J Artif Organs 2005; 28: 170–176 32. Yenic xerioglu Y, € Uzelce O, Akar H et al. Effects of atorvastatin on development of peritoneal fibrosis in rats on peritoneal dialysis. Ren Fail 2010; 32: 1095–1102 33. Rojas-Rivera J, De La Piedra C, Ramos A et al. The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant 2010; 25: 2850–2865